CYLC2

Across TCGA pan-cancer cohorts, CYLC2 Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated CYLC2 data layer compared with 12 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher CYLC2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CYLC2 expression acts as an unfavorable survival marker.

OV, HNSC, and DLBC are the cancer types where CYLC2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.282	0.692	.014	18	view →
HNSC	OS	Median	All	0.169	0.710	.008	18	view →
DLBC	OS	Median	II,III,IV	0.118	0.802	.025	12	view →
PRAD	OS	Median	All	0.145	0.883	<.001	12	view →
BLCA	OS	Median	IV	0.120	0.599	<.001	12	view →
LIHC	DFS	Median	II,III,IV	0.044	0.427	<.001	9	view →
LUSC	DFS	Median	III,IV	0.184	0.663	.010	9	view →
SARC	DFS	Median	All	0.159	0.613	.015	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

CYLC2–OV (OS)

Open the OV breakdown →